Brought to you by 
Pfizer licenses Kosan's motilin agonists
08 Jun 2021
Executive Summary
Cancer drug company Kosan Biosciences licensed Pfizer exclusive worldwide rights to its preclinical KOS2187 and other motilin agonists for gastrointestinal disorders.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer licenses Kosan's motilin agonists
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice